Syngene International, a leading contract research and manufacturing services firm, has taken a major step in expanding its global presence. The company has acquired its first biologics facility in the United States, which is equipped with multiple monoclonal antibody (mAbs) manufacturing lines. This move allows Syngene to increase its production capacity and improve supply continuity for its global customers.
The new site, acquired by Syngene USA Inc., a wholly owned subsidiary of Syngene, was previously owned by Emergent BioSolutions Inc. It will help the company expand its operations in both human and animal health sectors, ensuring a steady supply of biologics to clients across different markets. With this acquisition, Syngene’s total bioreactor capacity will reach 50,000L, making it a stronger player in large molecule discovery, development, and manufacturing.
For Syngene, this investment is more than just an expansion—it’s a move to deepen its footprint in the US market. The facility will not only help meet growing customer demand but also contribute to job creation and economic growth in the region. As the pharmaceutical industry continues to grow, having multiple facilities across India and North America gives Syngene a competitive edge in the global market.
The company already operates 4 development and manufacturing sites in India and North America. With this new addition, it will provide a more comprehensive range of services, including cell line development, process optimization, and clinical and commercial supply.
This acquisition is a win-win for Syngene and its customers. It ensures better supply chain stability, enhances innovation, and strengthens domestic biologics manufacturing in the US.